This is a demo store. No orders will be fulfilled.

Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Account

Bortezomib (PS-341)

Specifications & Purity: ≥98%

For research use only. We do not sell to patients.

Item Number
B125789
Grouped product items
SKU Size Availability Price Qty
B125789-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$61.90
B125789-25mg
25mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$154.90
B125789-100mg
100mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$411.90
B125789-250mg
250mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$350.90
B125789-500mg
500mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$1,441.90
B125789-1g
1g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$2,059.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET
Potent, selective, reversible\xa0proteasome inhibitor
main product photo

Basic Description

Synonyms PS-341;PS341;PS 341; Velcade;Radiciol;((1r)-3-methyl-1-(((2s)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-boronic acid; (R)-3-Methyl-1-((S)-3-phenyl-2-(pyrazine-2-carboxamido)propanamido)butylboronic acid, BTZ, LDP-341, LDP341, MG341, M
Specifications & Purity ≥98%
Storage Temp Store at -20°C
Shipped In Dry ice
Description

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
A selective and robust 26S proteasome inhibitor

Names and Identifiers

IUPAC Name [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
INCHI InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1
InChi Key GXJABQQUPOEUTA-RDJZCZTQSA-N
Canonical SMILES B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Alternate CAS 1610526-91-4,179324-69-7
PubChem CID 387447
NSC Number 681239
MeSH Entry Terms 341, PS;bortezomib;LDP 341;LDP-341;LDP341;PS 341;PS-341;PS341;Velcade
Molecular Weight 384.24

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

8 results found

Lot Number Certificate Type Date Item
K21251140 Certificate of Analysis Sep 12, 2023 B125789
K21251142 Certificate of Analysis Sep 12, 2023 B125789
F2215351 Certificate of Analysis Jun 01, 2022 B125789
F2215365 Certificate of Analysis Jun 01, 2022 B125789
F2215366 Certificate of Analysis Jun 01, 2022 B125789
F2215367 Certificate of Analysis Jun 01, 2022 B125789
G2307568 Certificate of Analysis Jun 01, 2022 B125789
H2325036 Certificate of Analysis Jun 01, 2022 B125789

Chemical and Physical Properties

Solubility Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol；Soluble in water 76 mg/l
Sensitivity light sensitive
Refractive Index 1.56
Boil Point(°C) 684.30° C
Melt Point(°C) 139-143°C

Related Document

 SDS

 Specification Sheet

Product Questions

Product Questions

Sign In Hover me Please sign in to submit a question
See all
No questions yet. Be the first to ask the question!

Reviews

Customer Reviews

Associated Targets

CTH Tchem Cystathionine gamma-lyase 7 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

C7orf77 Tdark Uncharacterized protein C7orf77 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

C8orf34 Tbio Uncharacterized protein C8orf34 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CGGBP1 Tbio CGG triplet repeat-binding protein 1 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

C8orf76 Tdark Uncharacterized protein C8orf76 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CHD1 Tbio Chromodomain-helicase-DNA-binding protein 1 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CHERP Tbio Calcium homeostasis endoplasmic reticulum protein 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CHP1 Tbio Calcineurin B homologous protein 1 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CAMTA2 Tbio Calmodulin-binding transcription activator 2 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CNBD1 Tdark Cyclic nucleotide-binding domain-containing protein 1 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CNBD2 Tdark Cyclic nucleotide-binding domain-containing protein 2 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

COMTD1 Tdark Catechol O-methyltransferase domain-containing protein 1 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

NCAPD3 Tbio Condensin-2 complex subunit D3 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CMTR2 Tbio Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 2 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CTNNBIP1 Tbio Beta-catenin-interacting protein 1 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CNDP2 Tbio Cytosolic non-specific dipeptidase 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

PDE6H Tclin Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CTDNEP1 Tbio CTD nuclear envelope phosphatase 1 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CNFN Tdark Cornifelin 0 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

CNKSR1 Tchem Connector enhancer of kinase suppressor of ras 1 30 Activities

Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

References

1. Reynolds JM, El Bissati K, Brandenburg J, Günzl A, Mamoun CB.  (2007)  Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL3B..  BMC Clin Pharmacol,  7  (11):  (13).  [PMID:17956613]
2. Ciechanover A.  (2005)  Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting (Nobel lecture)..  Angew Chem Int Ed Engl,  44  (37):  (5944-67).  [PMID:16142822]
3. Groll M, Berkers CR, Ploegh HL, Ovaa H.  (2006)  Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome..  Structure,  14  (3):  (451-6).  [PMID:16531229]
4. Bonvini P, Zorzi E, Basso G, Rosolen A.  (2007)  Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma..  Leukemia,  21  (4):  (838-42).  [PMID:17268529]
5. Nakamura H, Watanabe M, Ban HS, Nabeyama W, Asai A.  (2009)  Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors..  Bioorg Med Chem Lett,  19  (12):  (3220-4).  [PMID:19428245]
6. Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, Hu W, Liu Z.  (2017)  The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis..  Lupus,  26  (9):  (952-958).  [PMID:28059023]
7. Mazepa MA, Raval JS, Moll S, Ma A, Park YA.  (2014)  Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura..  Br J Haematol,  164  (6):  (900-2).  [PMID:24345005]
8. Wang Y, Zhou W, Zhang Z.  (2015)  Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient..  Rheumatology (Oxford),  54  (1):  (194-5).  [PMID:25288787]
9. Jakez-Ocampo J, Atisha-Fregoso Y, Llorente L.  (2015)  Refractory primary Sjögren syndrome successfully treated with bortezomib..  J Clin Rheumatol,  21  (1):  (31-2).  [PMID:25539431]
10. Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A et al..  (2015)  The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus..  Ann Rheum Dis,  74  (7):  (1474-8).  [PMID:25710470]
11. Xie SC, Gillett DL, Spillman NJ, Tsu C, Luth MR, Ottilie S, Duffy S, Gould AE, Hales P, Seager BA et al..  (2018)  Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome..  J Med Chem,  61  (22):  (10053-10066).  [PMID:30373366]
12. Abdin SM et al..  (2021)  Nuclear factor-?B signaling inhibitors revert multidrug-resistance in breast cancer cells..  Chem Biol Interact,  340  ():  (109450).  [PMID:33775688]
13. Kao CC et al..  (2022)  Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules..  Mol Ther Nucleic Acids,  27  ():  (335-348).  [PMID:35024245]
14. Gain C et al..  (2020)  Proteasomal inhibition triggers viral oncoprotein degradation via autophagy-lysosomal pathway..  PLoS Pathog,  16  (2):  (e1008105).  [PMID:32092124]
Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.